<DOC>
	<DOCNO>NCT00642239</DOCNO>
	<brief_summary>This multicentered clinical trial go find radio-sensitization action sodium glycididazole radiochemotherapy esophageal cancer .</brief_summary>
	<brief_title>A Clinical Trial Radiation Sensitizer Radiochemotherapy Thoracic Esophageal Squamous Carcinoma</brief_title>
	<detailed_description>Esophageal cancer one frequent cause cancer death world . The common type esophageal cancer squamous cell carcinoma ( SCC ) China . Although concurrent radiochemotherapy recommend standard treatment advance esophageal carcinoma , local failure still reach 44 % -54 % . Sodium Glycididazole ( CMNa ) radiosensitive drug hypoxic tumor cell . Clinical trial show CMNa improve local control rate survival rate esophageal cancer . This study go confirm efficacy safety CMNa concurrent radiochemotherapy radiotherapy 5-FU+DDP esophageal squamous carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>write informed consent photographically histologically proven thoracic esophageal squamous carcinoma stage 2a3 , stage 4 supraclavicular lymph node metastasis define AJCC ( 2002 ) radiochemotherapy indication measurable tumor adequate hematologic , hepatic renal function Karnofsky performance status â‰¥70 age 18years less 70 year pregnancy lactation significant neurologic disease severe liver renal malfunction , Significant medical illness previous chemotherapy , radiotherapy immunotherapy esophagus hemorrhage esophagus perforation feature</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Sodium Glycididazole , Radiochemotherapy , Esophageal Carcinoma</keyword>
</DOC>